Upregulation of ST3GAL5 predicts suppression of malignant biological behavior in bladder cancer

Abstract

Background: Bladder cancer (BLCA) is the most prevalent malignancy in the urinary tract system, while ST3GAL5 is a protein-coding gene that catalyzes the formation of ganglioside monosialodihexosylganglioside 3 (GM3) synthase. GM3 synthase has been reported to significantly influence the malignant process of various cancers. However, the expression profile and functional role of ST3GAL5 specifucally in BLCA remain to be elucidated.

Methods: In order to investigate the relationship between ST3GAL5 expression and malignant biological behavior and prognosis in BLCA. The mRNA expression of ST3GAL5 and clinicopathological characteristics in BLCA were firstly evaluated by public databases. Next, immunohistochemical staining was performed to analyze the protein expression of ST3GAL5 in BLCA and paracancerous tissues, as well as the expression of various types of malignant biological behavior. Subsequently, the gene set enrichment analyses (GSEA) were performed for ST3GAL5 and all correlated genes in BLCA by sorting Pearson's Correlation Coefficient. GSEA was also used to validate the pathways affected by the different expression levels of ST3GAL5 in BLCA patients.

Results: The mRNA and protein expression of ST3GAL5 in BLCA were significantly higher in low-grade and non-muscle-invasive BLCA (p < 0.05). The results from bioinformatics databases indicated that upregulation of ST3GAL5 have a lower grade, lower pathological stage, less susceptibility to lymphatic metastasis, and lower mortality rates. Kaplan-Meier survival analysis demonstrated that upregulation of ST3GAL5 was associated with better survival in BLCA (p < 0.05).

Conclusion: Upregulation of ST3GAL5 may be related to tumor suppression in BLCA, and may be a potential prognostic and therapeutic marker for BLCA.

Keywords

bladder cancer / immunohistochemistry / malignant biological behavior / ST3GAL5

References

[1] Siegel RL , Miller KD , Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69: 7- 34.

[2] Vos T , Allen C , Arora M , Barber RM , Bhutta ZA , Brown A , et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388: 1545- 602.

[3] Compérat EM , Burger M , Gontero P , Mostafid AH , Palou J , Rouprêt M , et al. Grading of urothelial carcinoma and the new "World Health Organisation classification of tumours of the urinary system and male genital organs 2016". Eur Urol Focus. 2019; 5: 457- 66.

[4] Magers MJ , Lopez-Beltran A , Montironi R , Williamson SR , Kaimakliotis HZ , Cheng L . Staging of bladder cancer. Histopathology. 2019; 74: 112- 34.

[5] Berselli P , Zava S , Sottocornola E , Milani S , Berra B , Colombo I . Human GM3 synthase: a new mRNA variant encodes an NH2-terminal extended form of the protein. Biochim Biophys Acta. 2006; 1759: 348- 58.

[6] Inokuchi JI , Inamori KI , Kabayama K , Nagafuku M , Uemura S , Go S , et al. Biology of GM3 Ganglioside. Prog Mol Biol Transl Sci. 2018; 156: 151- 95.

[7] Zheng C , Terreni M , Sollogoub M , Zhang Y . Ganglioside GM3 and Its Role in Cancer. Curr Med Chem. 2019; 26: 2933- 47.

[8] Hakomori SI , Handa K . GM3 and cancer. Glycoconj J. 2015; 32: 1- 8.

[9] Ouyang S , Liu JH , Ni Z , Ding GF , Wang QZ . Downregulation of ST3GAL5 is associated with muscle invasion, high grade and a poor prognosis in patients with bladder cancer. Oncol Lett. 2020; 20: 828- 40.

[10] Hutter C , Zenklusen JC . The cancer genome atlas: creating lasting value beyond its data. Cell. 2018; 173: 283- 5.

[11] Barrett T , Wilhite SE , Ledoux P , Evangelista C , Kim IF , Tomashevsky M , et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2012; 41: D991- 5.

[12] Kim WJ , Kim EJ , Kim SK , Kim YJ , Ha YS , Jeong P , et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010; 9: 3.

[13] Goldman MJ , Craft B , Hastie M , Repečka K , McDade F , Kamath A , et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020; 38: 675- 8.

[14] Liu B , Tang LH , Liu Z , Mei M , Yu R , Dhall D , et al. α-Internexin: a novel biomarker for pancreatic neuroendocrine tumor aggressiveness. J Clin Endocrinol Metab. 2014; 99: E786- 95.

[15] Yu G , Wang LG , Han Y , He QY . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16: 284- 7.

[16] Subramanian A , Kuehn H , Gould J , Tamayo P , Mesirov JP . GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics. 2007; 23: 3251- 3.

[17] R Core Team . R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020.

[18] Wickham H . ggplot2: elegant graphics for data analysis. 2nd ed. New York: Springer-Verlag; Bioinformatics. 2016.

[19] Miyazaki J , Nishiyama H . Epidemiology of urothelial carcinoma. Int J Urol. 2017; 24: 730- 4.

[20] Kaufman DS , Shipley WU , Feldman AS . Bladder cancer. Lancet. 2009; 374: 239- 49.

[21] van der Heijden AG , Witjes JA . Recurrence, progression, and follow-up in non-muscle-invasive bladder cancer. Eur Urol Suppl. 2009; 8: 556- 62.

[22] Huguet J . Seguimiento oncológico después de cistectomía radical basado en patrones de recidiva tumoral y sus factores de riesgo. Actas Urol Esp. 2013; 37: 376- 82.

[23] Soukup V , Babjuk M , Bellmunt J , Dalbagni G , Giannarini G , Hakenberg OW , et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol. 2012; 62: 290- 302.

[24] Vrooman OP , Witjes JA . Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice. Curr Opin Urol. 2010; 20: 437- 42.

[25] Bowser LE , Young M , Wenger OK , Ammous Z , Brigatti KW , Carson VJ , et al. Recessive GM3 synthase deficiency: Natural history, biochemistry, and therapeutic frontier. Mol Gen Metab. 2019; 126: 475- 88.

[26] Chung TW , Choi HJ , Kim SJ , Kwak CH , Song KH , Jin UH , et al. The ganglioside GM3 is associated with cisplatin-induced apoptosis in human colon cancer cells. PLoS One. 2014; 9: e92786.

[27] Li Q , Sun M , Yu M , Fu Q , Jiang H , Yu G , et al. Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker. Glycoconj J. 2019; 36: 419- 28.

[28] Guthmann MD , Castro MA , Cinat G , Venier C , Koliren L , Bitton RJ , et al. Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother. 2006; 29: 215- 23.

[29] Cai H , Zhou H , Miao Y , Li N , Zhao L , Jia L . MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5. Lab Invest. 2017; 97: 530- 42.

[30] Satoh M , Ito A , Nojiri H , Handa K , Numahata K , Ohyama C , et al. Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells. Int J Oncol. 2001; 19: 723- 31.

[31] Wang H , Isaji T , Satoh M , Li D , Arai Y , Gu J . Antitumor effects of exogenous ganglioside GM3 on bladder cancer in an orthotopic cancer model. Urology. 2013; 81: 210.e11- 210.e15.

RIGHTS & PERMISSIONS

The Author(s). UroPrecision published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.